[Form 4] CYTOKINETICS INC Insider Trading Activity

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and matching share sale in company common stock. On February 2, 2026, he exercised 886 shares under an incentive stock option at $37.63 per share.

The same day, he sold 886 common shares at $62.10 per share. After these transactions, Callos directly held 50,440 common shares and 886 incentive stock options. The option grant vests in equal monthly installments over four years from the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		M		886	A	$37.63	51,326	D
Common Stock	02/02/2026		S		886	D	$62.1	50,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	$37.63	02/02/2026		M			886	04/01/2025(1)	03/01/2032	Common Stock	886	$0	886	D

Explanation of Responses:

1. This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cytokinetics (CYTK) EVP Andrew Callos report?

Andrew Callos reported exercising 886 incentive stock options at $37.63 per share and selling 886 Cytokinetics common shares at $62.10 per share on February 2, 2026, as part of a routine Form 4 insider transaction disclosure.

How many Cytokinetics (CYTK) shares did Andrew Callos sell and at what price?

Andrew Callos sold 886 Cytokinetics common shares at $62.10 per share. The sale occurred on February 2, 2026, immediately following the exercise of an equal number of incentive stock options disclosed in the same insider filing.

What stock options did Andrew Callos exercise in Cytokinetics (CYTK)?

He exercised an incentive stock option covering 886 Cytokinetics common shares at an exercise price of $37.63 per share. The option grant vests in equal monthly installments over four years from the date of grant, according to the filing footnote.

How many Cytokinetics (CYTK) shares does Andrew Callos own after this Form 4?

Following the reported transactions, Andrew Callos directly held 50,440 Cytokinetics common shares. He also beneficially owned 886 derivative securities in the form of incentive stock options, as stated in the beneficial ownership tables in the insider report.

What is Andrew Callos’s role at Cytokinetics (CYTK) in this insider filing?

In this insider filing, Andrew Callos is identified as an officer of Cytokinetics, serving as Executive Vice President and Chief Commercial Officer. The Form 4 confirms he is not a director or 10% owner, but reports transactions as a senior executive.

How do Andrew Callos’s Cytokinetics (CYTK) options vest according to the filing?

The filing states the incentive stock option vests over four years in equal monthly installments. This schedule continues until the option is 100% vested four years from the grant date, providing a gradual monthly vesting of the underlying share rights.